Press coverage about Apellis Pharmaceuticals (NASDAQ:APLS) has been trending somewhat positive on Sunday, according to Accern Sentiment. The research firm identifies positive and negative media coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Apellis Pharmaceuticals earned a coverage optimism score of 0.23 on Accern’s scale. Accern also gave news coverage about the company an impact score of 45.8614067453094 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.

NASDAQ APLS traded down $0.30 during trading on Friday, reaching $18.51. 207,341 shares of the stock traded hands, compared to its average volume of 205,255. The company has a debt-to-equity ratio of 0.12, a quick ratio of 26.02 and a current ratio of 26.02. Apellis Pharmaceuticals has a fifty-two week low of $12.45 and a fifty-two week high of $32.00.

Apellis Pharmaceuticals (NASDAQ:APLS) last announced its quarterly earnings results on Tuesday, July 31st. The company reported ($0.61) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.47) by ($0.14). sell-side analysts forecast that Apellis Pharmaceuticals will post -2.2 earnings per share for the current fiscal year.

Several equities research analysts have recently commented on APLS shares. Cantor Fitzgerald started coverage on shares of Apellis Pharmaceuticals in a research report on Wednesday, May 23rd. They set an “overweight” rating for the company. B. Riley upgraded shares of Apellis Pharmaceuticals from a “neutral” rating to a “buy” rating and set a $27.00 price target for the company in a research report on Monday, July 30th. Cowen started coverage on shares of Apellis Pharmaceuticals in a research report on Tuesday, July 10th. They set an “outperform” rating and a $40.00 price target for the company. Finally, Zacks Investment Research cut shares of Apellis Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Friday, August 3rd. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and six have issued a buy rating to the company. The company presently has an average rating of “Buy” and an average price target of $36.00.

About Apellis Pharmaceuticals

Apellis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutic compounds for autoimmune and inflammatory diseases. Its lead product candidate is APL-2 to treat geographic atrophy, wet age-related macular degeneration, paroxysmal nocturnal hemoglobinuria, autoimmune hemolytic anemia, and nephrology.

Featured Article: What does earnings per share mean?

Insider Buying and Selling by Quarter for Apellis Pharmaceuticals (NASDAQ:APLS)

Receive News & Ratings for Apellis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apellis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.